Randomized Phase IIB Evaluation of Weekly Paclitaxel versus Weekly Paclitaxel with Oncolytic Reovirus (Reolysin®) in Recurrent Ovarian, Tubal, or Peritoneal Cancer: an NRG Oncology/Gynecologic Oncology Group Study

OBJECTIVE: To assess whether the addition of oncolytic reovirus (Reolysin®) to weekly paclitaxel prolonged progression-free survival (PFS) in the treatment of women with recurrent or persistent ovarian, tubal or primary peritoneal cancer. PATIENTS AND METHODS: Patients with recurrent or persistent e...

Full description

Saved in:
Bibliographic Details
Published in:Gynecol Oncol
Main Authors: Cohn, David E., Sill, Michael W., Walker, Joan L., O'Malley, David, Nagel, Christa I., Rutledge, Teresa L., Bradley, William, Richardson, Debra L., Moxley, Katherine M., Aghajanian, Carol
Format: Artigo
Language:Inglês
Published: 2017
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5570536/
https://ncbi.nlm.nih.gov/pubmed/28756871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2017.07.135
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items